EA200200097A1 - Имидазоимидазолы и триазолы в качестве противовоспалительных агентов - Google Patents

Имидазоимидазолы и триазолы в качестве противовоспалительных агентов

Info

Publication number
EA200200097A1
EA200200097A1 EA200200097A EA200200097A EA200200097A1 EA 200200097 A1 EA200200097 A1 EA 200200097A1 EA 200200097 A EA200200097 A EA 200200097A EA 200200097 A EA200200097 A EA 200200097A EA 200200097 A1 EA200200097 A1 EA 200200097A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imidazomidasoles
triazoles
inflammatory agents
international
application
Prior art date
Application number
EA200200097A
Other languages
English (en)
Other versions
EA004932B1 (ru
Inventor
Яньпин Ву
Теренс Алфред Келли
Рене М. Лемиё
Даниел Р. Голдберг
Джонатан Эмилиан Эми
Роналд Дж. Сорсек
Original Assignee
Бёрингер Ингельхайм Фармасьютиклз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фармасьютиклз, Инк. filed Critical Бёрингер Ингельхайм Фармасьютиклз, Инк.
Publication of EA200200097A1 publication Critical patent/EA200200097A1/ru
Publication of EA004932B1 publication Critical patent/EA004932B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

В заявке описаны соединения формулы (I), которые могут использоваться для лечения или предупреждения воспалительных и опосредуемых иммунными клетками заболеваний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200097A 1999-07-21 2000-07-12 Имидазоимидазолы и имидазотриазолы в качестве противовоспалительных агентов EA004932B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14490599P 1999-07-21 1999-07-21
US15093999P 1999-08-26 1999-08-26
PCT/US2000/018884 WO2001007440A1 (en) 1999-07-21 2000-07-12 Imidazoimidazoles and triazoles as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
EA200200097A1 true EA200200097A1 (ru) 2002-08-29
EA004932B1 EA004932B1 (ru) 2004-10-28

Family

ID=26842483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200097A EA004932B1 (ru) 1999-07-21 2000-07-12 Имидазоимидазолы и имидазотриазолы в качестве противовоспалительных агентов

Country Status (33)

Country Link
US (3) US6492408B1 (ru)
EP (1) EP1216247B1 (ru)
JP (1) JP2003505460A (ru)
KR (2) KR100767200B1 (ru)
CN (1) CN1166667C (ru)
AR (1) AR029383A1 (ru)
AT (1) ATE413402T1 (ru)
AU (1) AU776496B2 (ru)
BG (1) BG65865B1 (ru)
BR (1) BR0012666A (ru)
CA (1) CA2383017A1 (ru)
CO (1) CO5180640A1 (ru)
CZ (1) CZ2002191A3 (ru)
DE (1) DE60040751D1 (ru)
DK (1) DK1216247T3 (ru)
EA (1) EA004932B1 (ru)
EE (1) EE04965B1 (ru)
ES (1) ES2316374T3 (ru)
HK (1) HK1048637B (ru)
HR (1) HRP20020051A2 (ru)
HU (1) HUP0203971A3 (ru)
IL (2) IL147296A0 (ru)
MX (1) MXPA02000540A (ru)
MY (1) MY155218A (ru)
NO (1) NO322707B1 (ru)
NZ (1) NZ517217A (ru)
PL (1) PL352755A1 (ru)
RS (1) RS50260B (ru)
SK (1) SK286912B6 (ru)
TR (1) TR200200160T2 (ru)
TW (1) TWI261591B (ru)
UY (1) UY26249A1 (ru)
WO (1) WO2001007440A1 (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6414161B1 (en) 2000-08-09 2002-07-02 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis of (R)-3-(4-Bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-H-imidazo[1,2-a]imidazol-2-one
WO2002050080A1 (en) * 2000-12-19 2002-06-27 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
CA2434558A1 (en) * 2001-01-26 2002-08-01 Dmitry Zuev Imidazolyl derivatives as corticotropin releasing factor inhibitors
WO2003000657A1 (fr) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
DK1405852T3 (da) * 2001-06-20 2012-08-27 Daiichi Sankyo Co Ltd Diaminderivater
JP4331595B2 (ja) * 2001-08-09 2009-09-16 第一三共株式会社 ジアミン誘導体
FR2829766A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives d'oxamates comportant un heterocycle azote diversement substitue
WO2004032861A2 (en) 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
EP1712553A3 (en) * 2002-10-30 2006-11-02 Boehringer Ingelheim Pharmaceuticals, Inc. Derivates of [6, 7-dihydro - 5H - imidazo[1,2- alpha]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of CAMS and leukointegrins
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
RU2006144075A (ru) 2004-06-16 2008-07-27 Вайет (Us) ДИФЕНИЛИМИДАЗОПИРИМИДИН И -ИМИДАЗОЛАМИНЫ КАК ИНГИБИТОРЫ β-СЕКРЕТАЗЫ
CA2579724A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
RU2007106927A (ru) * 2004-07-27 2008-09-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Синтез амидов 6,7,-дигидро-5н-имидазо [1.2-а] имидазол-3-сульфоновой кислоты
TW200616634A (en) 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
MX2007004527A (es) * 2004-10-12 2007-09-21 Decode Genetics Inc Acidos carboxilicos biciclicos peri-sustituidos para enfermedad de arteria oclusiva.
US7186727B2 (en) 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
CN101103034A (zh) * 2005-01-14 2008-01-09 惠氏公司 抑制β-分泌酶的氨基-咪唑酮
RU2007124935A (ru) * 2005-02-01 2009-03-10 Вайет (Us) АМИНОПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКТРЕТАЗЫ
CN101146769A (zh) * 2005-02-14 2008-03-19 惠氏公司 作为β-分泌酶抑制剂的唑基酰基胍
US7572921B2 (en) * 2005-04-05 2009-08-11 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
EP1868603A1 (en) * 2005-04-06 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG DERIVATIVES OF Ý6,7-DIHYDRO-5HIMIDAZO Ýl,2-ALPHA¨IMIDAZOLE-3-SULFONYL¨-AZETEDINE-CARBOXYLIC ACIDS, ESTERS AND AMIDES AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS
MX2007014392A (es) * 2005-05-19 2008-02-06 Boehringer Ingelheim Int Derivados del acido 6, 7-dihidro-5h-imidazo [1,2-a] imidazol-3-sulfonico.
CA2609582A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
WO2007005404A1 (en) * 2005-06-30 2007-01-11 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
CN101273018A (zh) * 2005-09-26 2008-09-24 惠氏公司 用于β分泌酶（BACE）抑制剂的氨基-5-[4-(二氟甲氧基)苯基]-5-苯基咪唑酮化合物
JP2009520027A (ja) * 2005-12-19 2009-05-21 ワイス ２−アミノ−５−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用
EP1979309A2 (en) * 2006-01-20 2008-10-15 Boehringer Ingelheim International GmbH Process for the preparation of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid amides and intermediates used therein
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
JP2009539983A (ja) 2006-06-12 2009-11-19 シェーリング コーポレイション 複素環式アスパルチルプロテアーゼ阻害薬
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
AU2007293916B2 (en) 2006-09-07 2011-02-03 Emisphere Technologies, Inc. A process for the manufacture of SNAC (salcaprozate sodium)
CA2662348A1 (en) * 2006-09-21 2008-03-27 Wyeth Indolylalkylpyridin-2-amines for the inhibition of .beta.-secretase
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
PE20090160A1 (es) * 2007-03-20 2009-02-11 Wyeth Corp COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
PE20090617A1 (es) * 2007-03-23 2009-05-08 Wyeth Corp Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PT2225238E (pt) * 2007-11-29 2014-12-18 Boehringer Ingelheim Int Derivados de amidas do ácido 6,7-di-hidro-5h-imidazo[1,2- a]imidazol-3-carboxílico
JP5756457B2 (ja) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
EP2445914B1 (en) 2009-06-02 2015-07-22 Boehringer Ingelheim International GmbH DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
KR20120024699A (ko) 2009-06-02 2012-03-14 베링거 인겔하임 인터내셔날 게엠베하 ６，７－디하이드로－５Ｈ-이미다조［１，２－ａ］이미다졸－３－카복실산 아미드의 유도체
PL2448581T3 (pl) * 2009-06-29 2017-06-30 Agios Pharmaceuticals, Inc. Kompozycje terapeutyczne i odnośne sposoby ich stosowania
KR101712035B1 (ko) 2009-06-29 2017-03-03 아지오스 파마슈티컬스 아이엔씨. 치료용 화합물 및 조성물
US9221792B2 (en) 2010-12-17 2015-12-29 Agios Pharmaceuticals, Inc N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
JP6092118B2 (ja) 2010-12-21 2017-03-08 アジオス ファーマシューティカルズ， インコーポレイテッド ニ環式ｐｋｍ２活性化剤
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
ES2671581T3 (es) * 2011-07-13 2018-06-07 Tiumbio Co., Ltd. Imidazoles sustituidos con 2-piridilo como inhibidores de ALK5 y/o ALK4
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
MD3307271T2 (ro) 2015-06-11 2024-01-31 Agios Pharmaceuticals Inc Metode de utilizare a activatorilor de piruvat kinază
GB2560713A (en) * 2017-03-20 2018-09-26 Eternygen Gmbh Inhibitor of citrate transporter

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2015493A1 (ru) 1968-08-12 1970-04-30 Sumitomo Chemical Co
DK123717B (da) 1968-11-25 1972-07-24 Sumitomo Chemical Co 3-(3',5'-Dihalogenphenyl)-imidazolidin-2,4-dionderivater med mirobicid virkning.
DE2100800A1 (de) 1970-01-12 1971-07-15 Sumitomo Chemical Co Ltd , Osaka (Japan) Verfahren zur Herstellung von cycli sehen Arylimiden
JPS5136332B1 (ru) 1970-12-09 1976-10-07
JPS5188631A (en) 1975-01-31 1976-08-03 Hiiryoyosatsukinzai oyobi sonoseizoho
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
JPS60246374A (ja) 1984-05-18 1985-12-06 Daicel Chem Ind Ltd ２−アミノイミダゾリン化合物の製造方法
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5306822A (en) 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US4977270A (en) 1988-12-01 1990-12-11 Ici Americas Inc. Substituted 2,4-dioxodiazolidines and -thiadiazolidines and their use as herbicides
US4911748A (en) 1988-12-22 1990-03-27 Ici Americas Inc. Herbicidal 5-substituted-3-phenyl-imidazolidine-2,4-diones
JPH04273877A (ja) * 1991-02-28 1992-09-30 Sumitomo Pharmaceut Co Ltd 新規なイミダゾール誘導体
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
EA199900758A1 (ru) * 1997-03-03 2000-04-24 Бёрингер Ингельхайм Фармасьютиклс, Инк. Малые молекулы, полезные при лечении воспалительных заболеваний
ATE392894T1 (de) 1997-08-28 2008-05-15 Novartis Pharma Gmbh Lymphozyten funktion antigen-1 antagonisten
BR9909418A (pt) 1998-03-27 2001-09-25 Genentech Inc Antagonistas para o tratamento de distúrbios mediados por receptor de aderência cd11/cd18 e método para tratar ou melhorar uma resposta ou distúrbio imunológico ou inflamatório em um mamìfero mediada através da famìlia cd11/cd18 em moléculas de aderência celular
CA2378369C (en) * 1999-07-21 2007-10-02 Terence Alfred Kelly Small molecules useful in the treatment of inflammatory disease
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
EP1868603A1 (en) * 2005-04-06 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG DERIVATIVES OF Ý6,7-DIHYDRO-5HIMIDAZO Ýl,2-ALPHA¨IMIDAZOLE-3-SULFONYL¨-AZETEDINE-CARBOXYLIC ACIDS, ESTERS AND AMIDES AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS
MX2007014392A (es) * 2005-05-19 2008-02-06 Boehringer Ingelheim Int Derivados del acido 6, 7-dihidro-5h-imidazo [1,2-a] imidazol-3-sulfonico.

Also Published As

Publication number Publication date
AR029383A1 (es) 2003-06-25
JP2003505460A (ja) 2003-02-12
DK1216247T3 (da) 2009-02-23
CA2383017A1 (en) 2001-02-01
US20030203955A1 (en) 2003-10-30
HUP0203971A3 (en) 2005-01-28
HK1048637A1 (en) 2003-04-11
ATE413402T1 (de) 2008-11-15
AU6209100A (en) 2001-02-13
NO20020275L (no) 2002-02-04
TR200200160T2 (tr) 2002-10-21
EE200200028A (et) 2003-04-15
EA004932B1 (ru) 2004-10-28
BG65865B1 (bg) 2010-03-31
CZ2002191A3 (cs) 2002-04-17
US6492408B1 (en) 2002-12-10
HK1048637B (zh) 2005-02-25
NO20020275D0 (no) 2002-01-18
US7550494B2 (en) 2009-06-23
KR20070053363A (ko) 2007-05-23
NO322707B1 (no) 2006-11-27
EE04965B1 (et) 2008-02-15
YU3902A (sh) 2006-01-16
CN1372562A (zh) 2002-10-02
IL147296A0 (en) 2002-08-14
IL147296A (en) 2006-07-05
SK2562002A3 (en) 2002-07-02
EP1216247B1 (en) 2008-11-05
US20040116426A1 (en) 2004-06-17
RS50260B (sr) 2009-07-15
HRP20020051A2 (en) 2003-10-31
HUP0203971A2 (hu) 2003-03-28
ES2316374T3 (es) 2009-04-16
UY26249A1 (es) 2001-01-31
TWI261591B (en) 2006-09-11
CN1166667C (zh) 2004-09-15
BR0012666A (pt) 2002-04-09
MY155218A (en) 2015-09-30
US6689804B2 (en) 2004-02-10
DE60040751D1 (de) 2008-12-18
AU776496B2 (en) 2004-09-09
KR20020015074A (ko) 2002-02-27
BG106312A (bg) 2002-09-30
CO5180640A1 (es) 2002-07-30
NZ517217A (en) 2004-02-27
PL352755A1 (en) 2003-09-08
KR100767200B1 (ko) 2007-10-17
SK286912B6 (sk) 2009-07-06
MXPA02000540A (es) 2002-07-02
EP1216247A1 (en) 2002-06-26
WO2001007440A1 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200100772A1 (ru) Бензогетероциклы и их применение в качестве мек ингибиторов
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA199900936A1 (ru) Фунгицидные трифторметилалкиламинотриазолопиримидины
EA199900620A1 (ru) Фталазиноны
EA200101036A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
EA199800119A1 (ru) Ингибиторы адгезии клеток
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
EA200100757A1 (ru) Хинолинкарбоксамиды в качестве противовирусных агентов
EA200400006A1 (ru) Бензоилсульфонамиды и сульфонилбензамидины для применения в качестве противоопухолевых агентов
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
EA199901063A1 (ru) Пиперазиновые производные и их применение в качестве противовоспалительных агентов
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
EA200000871A1 (ru) Ингибиторы фосфолипазных ферментов
PT1109812E (pt) Pirrolobenzodiazepinas
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200100127A1 (ru) Производные фенилксантина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU